Several TNF-α–specific monoclonal antibodies (e.g., infliximab, adalimumab) and recombinant fusion proteins (etanercept), often developed for peripheral inflammatory conditions including Crohn’s disease and rheumatoid arthritis, have been tested on AD rodent models using both central and peripheral routes of administration (Chang et al., 2017; Decourt et al., 2017). This evidence concerns the gene TNF and Crohn disease.